Heron Therapeutics

HRTXPhase 3

San Diego, United StatesFounded 1983herontx.com

Heron Therapeutics is a publicly traded biopharmaceutical company dedicated to developing non-opioid, long-acting therapeutics for acute care and oncology supportive care. The company has successfully transitioned to a commercial entity with two marketed products and a pipeline leveraging its proprietary Biochronomer® sustained-release delivery technology. Heron's strategic focus is on expanding the commercial footprint of its approved products while advancing its pipeline candidates to address complex pain and nausea/vomiting challenges, aiming to reduce reliance on systemic opioids and improve patient outcomes.

Market Cap

$3.4B

Founded

1983

Employees

200-500

Focus

Biotech

HRTX · Stock Price

USD 18.265.48 (-23.08%)

Historical price data

AI Company Overview

Technology Platform

Biochronomer® polymer-based sustained-release drug delivery platform designed for localized, long-acting administration of therapeutic agents, enabling non-opioid pain management and extended-duration antiemetic therapy.

Pipeline Snapshot

28 drugs in pipeline, 6 in Phase 3

Drug	Indication	Stage
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine...	Analgesia	Approved
ZYNRELEF 200Mg-6Mg Extended-Release Solution	Post Operative Pain, Acute	Approved
SUSTOL	Chemotherapy-Induced Nausea and Vomiting (CINV)	Approved
Bupivacaine HCl	Analgesia	Approved
Bupivacaine Hydrochloride + Bupivacaine Hydrochloride + HTX-011 + Ibuprofen + Ac...	Analgesia	Approved

Funding History

Total raised: $215M

PIPE$125MUndisclosedJun 15, 2018

IPO$60MUndisclosedFeb 7, 2013

Series A$30MUndisclosedJan 15, 2007

Opportunities

Significant growth opportunity lies in the broad adoption of ZYNRELEF as a non-opioid standard of care across multiple surgical procedures, including expansion into new indications like cesarean section and pediatric use.

International market expansion and potential label extensions for its products represent additional avenues for revenue growth.

Risk Factors

Key risks include commercial execution challenges in a competitive pain management market, dependence on the successful uptake of ZYNRELEF, ongoing pricing and reimbursement pressures, and the potential need for additional capital financing if revenue growth lags expectations.

Competitive Landscape

Heron's main competitors include Pacira BioSciences (Exparel®/liposomal bupivacaine) in post-operative pain and generic 5-HT3 antagonists in CINV. Heron differentiates through its Biochronomer® platform, which enables fixed-dose combination products (like bupivacaine/meloxicam) for multi-mechanistic pain relief and extended-duration efficacy from a single administration.